Peptide Companion
Peptide Companion
blend
Weight Management
Vial: 12 mg

How is AOD-9604 + CJC-1295 + Ipamorelin (12 mg Blend) dosed and mixed?

AOD-9604 + CJC-1295 + Ipamorelin (12 mg Blend) is a peptide blend research reference in the Weight Management category for a 12 mg vial. The reference mixing guide adds 3 mL of bacteriostatic water, giving a concentration of 4 mg/mL. The published research schedule lists 0.2–0.3 mg per injection, 2–3 times daily for 8–12 weeks; it is reference information, not a recommendation.

By Vincent Ceniceros · Published · Last updated

This synergistic blend combines three peptides targeting body composition: AOD-9604 (hGH fragment 177–191) promotes lipolysis without raising IGF-1; CJC-1295 (GHRH analog) produces sustained GH and IGF-1 elevations; and Ipamorelin (ghrelin mimetic) selectively stimulates GH secretion without increasing cortisol or ACTH. Together, these peptides may support lean mass gains and fat reduction.

Dose
0.2–0.3 mg per injection
Frequency
2–3 times daily
Timing
Morning, post-workout, before bed
Duration
8–12 weeks

Selective GH secretagogue. Minimal cortisol/prolactin elevation. Excellent safety profile.

Dosing Schedule
WeekDaily DoseUnits (mL)
Week 1200 mcg AOD / 100 mcg CJC / 100 mcg Ip10 units (0.10 mL)
Week 2300 mcg AOD / 150 mcg CJC / 150 mcg Ip15 units (0.15 mL)
Weeks 3–12400 mcg AOD / 200 mcg CJC / 200 mcg Ip20 units (0.20 mL)
Mixing & Quick Reference
Bacteriostatic water
3 mL
Concentration
4 mg/mL
  • •Vial contents: 6 mg AOD-9604 + 3 mg CJC-1295 + 3 mg Ipamorelin (12 mg total).
  • •Reconstitute: Add 3.0 mL bacteriostatic water → 4 mg/mL total (2 mg/mL AOD, 1 mg/mL CJC, 1 mg/mL Ip).
  • •Typical daily range: 0.1–0.2 mL once daily (200–400 mcg AOD / 100–200 mcg CJC / 100–200 mcg Ip).
  • •Easy measuring: At 4 mg/mL total, 1 unit = 0.01 mL = 40 mcg total (20 mcg AOD + 10 mcg CJC + 10 mcg Ip).
  • •Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Supplies Needed
  • •Peptide Blend Vials (12 mg each): - 8 weeks (~11.2 mL total): 4 vials - 12 weeks (~16.8 mL total): 6 vials - 16 weeks (~22.4 mL total): 8 vials
  • •Insulin Syringes (U‑100): - Per week: 7 syringes (1/day) - 8 weeks: 56 syringes - 12 weeks: 84 syringes - 16 weeks: 112 syringes
  • •Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution. - 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles - 12 weeks (6 vials): 18 mL → 2 × 10 mL bottles - 16 weeks (8 vials): 24 mL → 3 × 10 mL bottles
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each day. - Per week: 14 swabs (2/day) - 8 weeks: 112 swabs → recommend 2 × 100‑count boxes - 12 weeks: 168 swabs → recommend 2 × 100‑count boxes - 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
How It Works

This blend combines three complementary peptides with distinct mechanisms:

- AOD-9604 is a modified C-terminal fragment of human growth hormone (amino acids 177–191) that retains the lipolytic and anti-lipogenic properties of GH without stimulating IGF-1 or affecting glucose metabolism. - CJC-1295 is a long-acting GHRH analog that produces sustained elevations in growth hormone and IGF-1 levels, supporting anabolic processes and fat metabolism. - Ipamorelin is a selective ghrelin mimetic that stimulates pulsatile GH secretion without significantly increasing ACTH or cortisol, offering a cleaner GH release profile.

Together, these peptides work synergistically to enhance endogenous GH pulsatility and promote favorable changes in body composition similar to exogenous GH therapy.

References and original studies

  • Journal of Endocrinology & Metabolism (2014)

    Safety and metabolism of AOD9604: novel nutraceutical ingredient for improved metabolic health

    View source

  • Journal of Clinical Endocrinology & Metabolism (PubMed)

    Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults

    View original study

  • European Journal of Endocrinology (PubMed)

    Ipamorelin: the first selective growth hormone secretagogue

    View original study

  • Translational Andrology and Urology (PMC)

    Role of growth hormone secretagogues in body composition management

    View original study

  • Endocrinology (OUP)

    hGH and AOD-9604: lipid metabolism and beta-adrenergic pathway insights

    View source

  • CDC

    Preventing unsafe injection practices: multi-dose vial handling guidelines

    View source

  • Journal of Endocrinology & Metabolism (2013)

    Safety and tolerability of the hexadecapeptide AOD9604 in humans

    View source

  • Obesity Pharmacotherapy Review (PMC)

    AOD-9604 clinical trial overview and weight loss outcomes

    View original study

  • Subcutaneous Drug Injection Review (PMC)

    Pharmacologic considerations of the subcutaneous route

    View original study

  • CDC

    Vaccine administration: subcutaneous route (angle/site guidance)

    View source

  • MedlinePlus

    Subcutaneous injections: patient instructions and technique

    View source

  • NCBI Bookshelf

    Best practices for injection: asepsis, preparation, and administration

    View original study

  • Central & Peripheral Anti-Obesity Targets (PMC)

    AOD-9604 RCT summary and mechanistic overview

    View original study

  • PubMed

    Metabolic studies of AOD-9604 in obese rodents (oral dosing, fat oxidation)

    View original study

About the author

Vincent Ceniceros

Vincent Ceniceros created Peptide Companion and publishes its Dosage Library. Each guide summarizes a reference protocol and links to the studies and sources it draws on.

Published · Last updated

Related guides

Work out the mixing math for any vial with the peptide reconstitution calculator, or browse the full Dosage Library.

Educational content adapted from peptidedosages.com. Not medical advice.